Roche and Broad Clinical Labs Partner to Advance SBX Sequencing Adoption
Roche and Broad Clinical Labs Partner to Advance Genomic Applications with SBX Sequencing Technology Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced a strategic collaboration with Broad Clinical Labs, aimed at exploring and developing innovative applications using Roche’s new Sequencing…
Eli Lilly Shares Presentation Details for 2025 ASCO Annual Meeting
Eli Lilly to Present New Data on Imlunestrant, Olomorasib, LY4170156, and Verzenio® at 2025 ASCO Annual Meeting Eli Lilly and Company (NYSE: LLY) announced today that new clinical data from its oncology pipeline—including imlunestrant, olomorasib, LY4170156, and Verzenio® (abemaciclib)—will be…
BeiGene Showcases Groundbreaking Cancer Research at ASCO 2025
New data from SEQUOIA, to be reported in two oral presentations, underscore the benefits of BRUKINSA® as first-line treatment for patients with chronic lymphocytic leukemia (CLL) Promising early phase data show the strength of the pipeline in treating multiple solid tumor…
Court Approves CVS Health’s Bids for Rite Aid Assets
The U.S. Bankruptcy Court of New Jersey approved CVS Pharmacy® bids on the prescription files of 625 Rite Aid pharmacies across 15 states in areas that CVS serves, as well 64 Rite Aid stores in Idaho, Oregon and Washington. The transaction…
J&J MedTech Launches SOUNDSTAR CRYSTAL™ in US, Elevating 2D Intracardiac Imaging Clarity
Johnson & Johnson MedTech Launches SOUNDSTAR CRYSTAL™ Ultrasound Catheter in the U.S. to Enhance Cardiac Ablation Procedures May 2025 – Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, has announced the U.S. launch of the SOUNDSTAR CRYSTAL™…
Advocating for Comprehensive Insurance Coverage for People Affected by Obesity
Access to Obesity Medications Shouldn’t Be This Hard Recent changes in insurance coverage have forced thousands of Americans living with obesity into an impossible choice: stop taking a safe, effective medication recommended by their health care provider—or pay out of…
Lilly’s Kisunla Approved in Australia for Early Alzheimer’s Treatment
Eli Lilly’s Kisunla Receives Regulatory Approval in Australia for Early Alzheimer’s Treatment Eli Lilly and Company (NYSE: LLY) announced today that Australia’s Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (donanemab), an intravenous infusion therapy administered every four…
Aetna Better Health of Illinois Invests $20.4 Million to Improve Health Outcomes Statewide
Aetna Better Health® of Illinois Invests $20.4 Million in Value-Based Care to Improve Health Outcomes in Underserved Communities Aetna Better Health® of Illinois, a CVS Health® company (NYSE: CVS), has distributed $20.4 million in value-based care incentive payments to several…
AstraZeneca Marks Seventh Consecutive Year of Plenary Data at ASCO, Advancing Breast and Gastric Cancer Care
AstraZeneca Showcases Oncology Breakthroughs at ASCO 2025, Reinforcing Mission to Eliminate Cancer as a Cause of Death AstraZeneca will present new data from over 80 abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 –…
Roche Updates on FDA Panel Review of Columvi Combo for Relapsed DLBCL
Roche Presents Positive ODAC Discussion on Columvi® Combination Therapy for Aggressive Lymphoma Basel, Switzerland – May 21, 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) held…
Cytokinetics Shares New Aficamten Data at ESC Heart Failure 2025 Congress
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data arising from two analyses from SEQUOIA-HCM, (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), and results from a real-world analysis related to…
Makary’s ‘Conditional Approval’ Plan for Rare Diseases Raises More Questions Than It Answers
FDA Under Makary Eyes New Pathway for Rare Disease Drugs Amid Debate Over Feasibility and Safety While the U.S. Food and Drug Administration (FDA) under new Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. may seem a far…